Streetbeat News

Earnings

ABOS

Acumen Pharmaceuticals (NASDAQ:ABOS) is scheduled to release its quarterly earnings report on March 26, 2024, with an expected EPS of $-0.26. The company's past earnings performance shows a mixed pattern of beating and missing EPS estimates, leading to varying stock price reactions. Shares of Acumen Pharmaceuticals have seen a 6.98% increase over the last 52 weeks, trading at $4.3 as of March 22. Investors are looking forward to not only the earnings results but also the company's future guidance.

Portfolio Pulse from Benzinga Insights

March 25, 2024 | 4:05 pm

INTZ

Intrusion (NASDAQ:INTZ) is scheduled to release its quarterly earnings report on March 26, 2024, with analysts expecting an EPS of $-0.11. The company's past earnings performance shows a trend of missing EPS estimates, leading to significant drops in share price the following day. Shares of Intrusion have decreased by 83.02% over the last 52 weeks, indicating a bearish outlook from long-term shareholders ahead of the earnings release.

Portfolio Pulse from Benzinga Insights

March 25, 2024 | 4:05 pm

DCTH

Delcath Systems (NASDAQ:DCTH) is scheduled to release its quarterly earnings report on March 26, 2024, with an expected EPS of $-0.51. The company's past earnings performance shows a pattern of not meeting EPS estimates, leading to significant share price drops. Shares are currently trading at $4.68, down 19.09% over the last year. Investors are looking for positive guidance for the next quarter.

Portfolio Pulse from Benzinga Insights

March 25, 2024 | 4:05 pm

BRAG

Bragg Gaming Group (NASDAQ:BRAG) is scheduled to release its quarterly earnings report on March 26, 2024, with an estimated EPS of $-0.01. Historical performance shows mixed results with the last quarter missing estimates by $0.11, leading to no change in stock price the following day. Over the last year, BRAG shares have increased by 42.42%, indicating a positive outlook from long-term shareholders.

Portfolio Pulse from Benzinga Insights

March 25, 2024 | 4:05 pm

BIOR

Biora Therapeutics (NASDAQ:BIOR) is scheduled to release its quarterly earnings report on March 26, 2024, with analysts expecting an EPS of $-0.59. Historical data shows mixed reactions to past earnings, with the last quarter beating estimates by $0.01 but resulting in a 2.19% share price drop. Over the last year, BIOR shares have declined by 53.88%, indicating a bearish outlook among long-term investors.

Portfolio Pulse from Benzinga Insights

March 25, 2024 | 4:05 pm

CGTX

Cognition Therapeutics (NASDAQ:CGTX) is scheduled to release its quarterly earnings report on 2024-03-26, with an estimated EPS of $-0.34. Investors are hopeful for a beat on this estimate and positive guidance for the next quarter. Historically, CGTX has shown a mixed reaction to earnings reports, with share price movements varying post-announcement. Currently, shares are trading at $1.81, down 10.78% over the last 52 weeks.

Portfolio Pulse from Benzinga Insights

March 25, 2024 | 4:05 pm

PAVM

PAVmed Inc. (NASDAQ:PAVM) is scheduled to release its quarterly earnings report on March 26, 2024, with analysts expecting an EPS of $-1.89. The company's past earnings performance shows a mixed record of beating and missing EPS estimates, leading to varied stock price reactions. Shares of PAVmed have declined by 55.27% over the last 52 weeks, indicating a bearish sentiment among long-term shareholders. Investors will be keenly watching for the company's performance against the EPS estimate and any forward-looking guidance provided.

Portfolio Pulse from Benzinga Insights

March 25, 2024 | 4:05 pm

ALV

Over the last three months, Autoliv (NYSE:ALV) has been evaluated by 5 analysts, showing a positive shift in sentiment with an increase in the average 12-month price target to $113.8 from $105.40. Analysts from Mizuho and Barclays have raised their price targets, reflecting optimism in Autoliv's financial performance, which includes a solid revenue growth rate of 17.82% and impressive net margin and ROE figures. Autoliv is recognized as a global leader in passive safety components for the auto industry.

Portfolio Pulse from Benzinga Insights

March 25, 2024 | 4:05 pm

PBLA

Panbela Therapeutics (NASDAQ:PBLA) is scheduled to release its quarterly earnings report on March 26, 2024, with an estimated EPS of $-24.34. Historical data shows mixed reactions to past earnings reports, with the last quarter missing EPS estimates and resulting in a 2.66% share price increase the following day. Over the past year, PBLA shares have declined by 99.79%, indicating significant investor concern ahead of this earnings announcement.

Portfolio Pulse from Benzinga Insights

March 25, 2024 | 4:05 pm

PUBM

Analyst reviews for PubMatic (NASDAQ:PUBM) over the last three months show diverse outlooks, with recent ratings becoming more bullish. The average 12-month price target has increased to $26.00, reflecting a 34.51% rise from the previous target of $19.33. PubMatic's financial performance is strong, with significant revenue growth, high net margin, and excellent ROE and ROA, outperforming industry averages. The company's debt management is also sound, indicating a robust financial structure.

Portfolio Pulse from Benzinga Insights

March 25, 2024 | 4:05 pm